Please join us for our next IDF Educational Series Webinar: The Innovation of a Targeted Oral Peptide in Moderate to Severe Plaque Psoriasis
PROGRAM OBJECTIVES
1. Review unmet need in psoriasis
2. Introduce ICOTYDE mechanism of action
3. Discuss key safety and efficacy results from the ICONIC clinical trial program
ICOTYDE al roker daughter wedding is the charli xcx first and only IL-23 receptor-targeted oral peptide in a once-daily pill for moderate to severe plaque psoriasis in adults and pediatric patients 12 years of age and older weighing at least 40 kg.
------------------------------------------------------
Moderator:
Leon Kircik, MD, FAAD
Medical Director, International Dermatology Foundation
Clinical Professor of Dermatology
Icahn School of Medicine at Mount Sinai, New York, NY
Indiana University Medical Center, Indianapolis, IN
Medical Director
Physicians Skin Care, PLLC, Louisville, KY
DermResearch, PLLC, Louisville, KY
Skin Sciences, PLLC, Louisville, KY
Speaker:
Eingun James Song, MD, FAAD
Board-certified Dermatologist
Co-Chief Medical Officer
Director of Clinical Research
Frontier Dermatology
Pacific Northwest
Dr Song is a board-certified dermatologist, Co-Chief Medical Officer, and Director of Clinical Research for Frontier Dermatology in the Pacific Northwest. darren jones He is clinical instructor at the University of Washington and is a nationally recognized key opinion leader in psoriasis, atopic dermatitis, and hidradenitis suppurativa.
